Series A · Biotech · Uppsala, Sweden · Founded 2021 · 8–10 employees
Akiram Therapeutics is a Swedish biotech company developing targeted radioimmunotherapy for cancer using a proprietary antibody that targets the CD44v6 cancer marker combined with radioactive lutetium-177. The company's lead drug candidate 177Lu-AKIR001 is currently in Phase 1 clinical trials at Karolinska University Hospital, representing potentially the first-in-class treatment for aggressive cancers including anaplastic thyroid cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. The company has raised $6.5M in Series A funding and has demonstrated promising preclinical results in cancer models where effective treatments are currently lacking.
No open roles listed right now.